ArticleFrontiers in bioengineering and biotechnology2024
Engineered myeloid precursors differentiate into osteoclasts and resorb heterotopic ossification in mice.
Article in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Calcific Aortopathy in Response to Aging and Injury.Circulation · 2026Review
- From 5F hematopoietic progenitors to osteoclasts: a scalable human model of osteoclastogenesis.Frontiers in cell and developmental biology · 2026Article
- Differentiation and Characterization of Osteoclasts from Human Induced Pluripotent Stem Cells.Journal of visualized experiments : JoVE · 2024Article
- Comparison of osteoclast differentiation protocols from human induced pluripotent stem cells of different tissue origins.Stem cell research & therapy · 2023Article
- Comparison of osteoclast differentiation protocols from human induced pluripotent stem cells of different tissue origins.Research square · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Introduction: Heterotopic ossification (HO) occurs following orthopedic trauma, spinal cord injuries, brain trauma and limb amputations. Once symptomatic, HO causes pain, limited mobility and decreased quality of life. Current treatments are limited and have significant complications with high recurrence rates, underscoring the need for improved therapeutic interventions. Osteoclasts (OCs) are physiological bone resorptive cells that secrete enzymes and protons to degrade bone. Methods: In this study, we describe the use of genetically engineered OCs as a novel cell therapy approach to treat HO. Inducible, engineered myeloid precursors (iRANK cells) treated with a chemical inducer of dimerization (CID) differentiated into TRAP Results: Discussion: In summary, these data con rm the ability of engineered myeloid precursors to differentiate into OCs and resorb HO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.